1An ASCO Allied Physician/Doctoral Scientist may only sponsor his or her own abstract as first author. 2An ASCO Member in Training who sponsors his or her own abstract must also obtain a signature from the training program director. (The training program director does not have to be an ASCO...
1An ASCO Allied Physician/Doctoral Scientist may only sponsor his or her own abstract as first author. 2An ASCO Member in Training who sponsors his or her own abstract must also obtain a signature from the training program director. (The training program director does not have to be an ASCO...
12. Xicheng Wang, et al. Encorafenib and cetuximab versus irinotecan/cetuximab or FOLFIRI/cetuximab in Chinese patients with BRAF V600E mutant metastatic colorectal cancer: The NAUTICAL CRC study. 2024 ASCO Abstract #LBA3559....
2.Ken Kato, Yuichiro Doki, Ian Chau, et al.Nivolumab plus chemotherapy or ipilimumab versus chemotherapy in patients with advanced esophageal squamous cell carcinoma (CheckMate 648): 29-month follow-up from a randomized, open-label, phase III trial. 2024 asco abstract 4000. 3.Ulka N. Vaisham...
Abstract 5053 恩扎卢胺 vs. 阿比特龙在真实世界老年mCRPC患者中的有效性与心血管安全性[1] 研究背景 阿比特龙和恩扎卢胺已广泛用于mCRPC患者的治疗,并已扩展至去势敏感和非转移性疾病的治疗。本研究旨在对比真实世界中老年mCRPC患者首次接受...
NEW YORK,May 23, 2024/PRNewswire/ --Belong.Life, a leading global provider of AI-powered patient education and support solutions, announced today that theAmerican Society of Clinical Oncology (ASCO)has published an abstract in its 2024...
2024 ASCO 2024年5月31日-6月4日,2024年美国临床肿瘤学会(ASCO)年会于美国芝加哥正式召开。中国医学论坛报学术联播持续关注大会前沿,推出“一分钟要闻”板块,为您网罗大会新鲜资讯,浓缩学术前沿精华! 研究概要 标题:2024ASCO年会重磅研究速递Abstract1003
of chemotherapy (TPC) in patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor receptor 2 (HER2)-low or HER2-ultralow metastatic breast cancer (mBC) with prior endocrine therapy (ET): Primary results from DESTINY-Breast06 (DB-06). ASCO 2024; Abstract LBA 1000...
其二是SKB264联合PD-L1单抗KL-A167一线治疗晚期非小细胞肺癌的临床二期OptiTROP-Lung01研究的最新数据（NCT05351788），将于Oral Abstract Session口头汇报，摘要号为8502。ADC+IO正在开启肿瘤免疫治疗新时代之际，科伦博泰也在积极布局。可见，成功牵手默沙东，并作为默沙东肿瘤管线未来的重要产品之一，SKB264正在国际舞台...
备受关注的ASCO Plenary Series: Rapid Abstract Updates(ASCO全体会议系列:摘要更新)将于6月1日12:30-13:30(芝加哥时间)在会议展馆的Arie Crown Theater举行,在该活动的6个摘要更新中,中国研究占据“半壁江山”: Updates on Abstract 434420: A Phase 1 Trial of Claudin 18.2-Specific Antibody-Drug Conjugate ...